Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lung Neoplasms 3Thrombosis 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Esophageal Squamous Cell Carcinoma 2Disease 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytopenia 1Thoracic Neoplasms 1Skin Neoplasms 1Pituitary Neoplasms 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Pancreatic Cancer × Injections × Clear all
NCT06492941 2024-07-09

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡